Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pieris Pharmaceuticals, Inc. PIRS
$0.86
-$0.08 (-9.33%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
66530656.00000000
-
week52high
2.12
-
week52low
0.72
-
Revenue
25902000
-
P/E TTM
-2
-
Beta
1.08269800
-
EPS
-0.49000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:00
Описание компании
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Baird | Outperform | Neutral | 13 мар 2020 г. |
| Baird | Neutral | Outperform | 30 июл 2019 г. |
| Baird | Outperform | 14 мая 2019 г. | |
| Cowen & Co. | Outperform | 04 мая 2018 г. | |
| Jefferies | Buy | Buy | 19 мар 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kiener Peter A | A | 40000 | 40000 | 22 июн 2022 г. |
| GERAGHTY JAMES A | A | 45000 | 45000 | 22 июн 2022 г. |
| Said Maya R. | A | 40000 | 40000 | 22 июн 2022 г. |
| Barbier Ann | A | 40000 | 40000 | 22 июн 2022 г. |
| Sherman Matthew L | A | 40000 | 40000 | 22 июн 2022 г. |
| Richman Michael | A | 40000 | 40000 | 22 июн 2022 г. |
| KIRITSY CHRISTOPHER P | A | 40000 | 40000 | 22 июн 2022 г. |
| Demuth Tim | A | 6000 | 6000 | 13 мая 2022 г. |
| Yoder Stephen S. | A | 625874 | 625874 | 22 февр 2022 г. |
| Olwill Shane | A | 215819 | 215819 | 22 февр 2022 г. |
Новостная лента
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
PennyStocks
12 мая 2023 г. в 11:16
Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now?
Best Penny Stocks to Buy? 3 Under $1 To Watch Before Next Week
PennyStocks
11 мая 2023 г. в 13:23
Penny stocks under $1 to watch right now. The post Best Penny Stocks to Buy?
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 09:56
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Accesswire
02 мая 2023 г. в 16:30
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 866-682-6100 (Toll Free US & Canada) or +1 862-298-0702 (International) at least five minutes prior to the start of the call.
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 мар 2023 г. в 15:40
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer Mary Fitzgerald - Vice President, Project Leader Elarekibep Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Rob Andrew - William Blair & Company Operator Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. [Operator Instructions].